Beyond Air, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Beyond Air, Inc. (XAIR) on March 17, 2020. The Company, an emerging growth company, reported the entry into a material definitive agreement by its wholly owned subsidiary, Beyond Air Ireland Limited ("BAL").
Key Financial Metrics and Obligations
The filing details a new credit facility rather than historical financial performance metrics such as revenue or profit.
- Total Facility Size: Up to $25,000,000.
- Structure: Five tranches of $5,000,000 each.
- Initial Draw: Tranche One ($5,000,000) was borrowed on March 17, 2020.
- Interest Rate: 10% per annum.
- Repayment Terms: Installments commence June 15, 2023; final maturity date is March 17, 2025.
- Equity Component: Issuance of 172,187 five-year warrants with an exercise price of $7.26 per share upon the initial draw.
Material Changes and Conditions
The primary material change is the creation of a direct financial obligation. Access to future funding is contingent on regulatory milestones:
- Tranches Three through Five may only be utilized following FDA approval of the Company's LungFit PH product.
- Warrants issued for Tranches Two through Five will have an exercise price equal to the greater of $3.66 per share or the five-day VWAP prior to the utilization date.
Outlook, Risks, and Contingencies
The Company's ability to access the remaining $20,000,000 of the facility is directly tied to the success of its LungFit PH product in obtaining FDA approval. The filing notes that loans may be prepaid subject to certain prepayment penalties. No specific management commentary regarding future revenue guidance or operational outlook was provided in this specific filing.
Key Facts for Investor Verification
- Verify the current status of the LungFit PH product's FDA approval process, as this gates access to 80% of the total facility.
- Review the full Facility Agreement (Exhibit 10.1) for details on prepayment penalties and specific covenant requirements.
- Monitor the dilution impact of the initial 172,187 warrants and potential future warrant issuances tied to subsequent tranches.
- Confirm the Company's cash burn rate to assess the necessity of drawing down Tranche Two prior to the FDA approval milestone.